Powering the Immune System to Transform Lives

Ruju Srivastava photoRuju Bhatt Srivastava, M.D.


Ruju Srivastava, M.D. has served as Vir’s Executive Vice President, Program Leadership and Management since April 2024. Over the course of her career, Dr. Srivastava has brought both scientific and strategic perspectives to portfolio management, drug development and business development. She is responsible for overseeing Vir’s end-to-end program strategy including the planning and executional imperatives for Vir’s clinical development assets. 

Before joining Vir, Dr. Srivastava served as Vice President, Product Development at Gritstone bio, where she was responsible for cross-functional development of immuno-oncology and infectious disease therapies. Prior to joining Gritstone, she served as Executive Director, Product Development at BioMarin Pharmaceutical Inc. where she led a Phase 3 oncology program and a first-in-human rare disease program. Prior to that, Dr. Srivastava spent 13 years at Millennium/Takeda, where she worked in mergers and acquisitions and product licensing, as well as in oncology drug development.

Dr. Srivastava earned her M.D. at Harvard Medical School. She also received a Master of Philosophy from the University of Oxford, as well as a B.S. in Biochemistry and B.A. in International Relations from Michigan State University.